Get the Stockscreener App
1.79
0.00%
0.00
Skye Bioscience Inc stock is traded at $1.79, with a volume of 55,932.
It is up +0.00% in the last 24 hours and down -24.15% over the past month.
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
See More
Previous Close:
$1.79
Open:
$1.82
24h Volume:
55,932
Relative Volume:
0.09
Market Cap:
$44.45M
Revenue:
-
Net Income/Loss:
$-21.24M
P/E Ratio:
-2.1363
EPS:
-0.8379
Net Cash Flow:
$-22.47M
1W Performance:
+24.74%
1M Performance:
-24.15%
6M Performance:
-64.41%
1Y Performance:
-86.07%
1-Day Range:
$1.76
$1.87
1-Week Range:
$1.36
$1.85
52-Week Range:
$1.14
$13.51
Skye Bioscience Inc Stock (SKYE) Company Profile
Name
Skye Bioscience Inc
Sector
Industry
Phone
(858) 410-0266
Address
11250 EL CAMINO REAL, SUITE 100, SAN DIEGO
Compare SKYE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SKYE
Skye Bioscience Inc.
|
3.10 | 12.89M | 0 | 0 | 0 | 0.00 |
|
MOBBW
Mobilicom Limited Warrants
|
0.24 | 398.00M | 0 | 0 | 0 | 0.00 |
|
GOODO
Gladstone Commercial Corporation
|
19.91 | 372.90M | 0 | 0 | 0 | 0.00 |
|
PSNYW
Polestar Automotive Holding Uk
|
0.1699 | 362.35M | 2.07B | -1.42B | -1.37B | -0.6765 |
|
JUNE
Dhandho Junoon Etf
|
10.81 | 218.53M | 0 | 0 | 0 | 0.00 |
|
SHMD
Schmid Group N V
|
3.605 | 125.31M | 0 | 0 | 0 | 0.00 |
Skye Bioscience Inc Stock (SKYE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-28-25 | Initiated | William Blair | Outperform |
| Sep-30-24 | Initiated | Scotiabank | Sector Outperform |
| Sep-10-24 | Initiated | JMP Securities | Mkt Outperform |
| Jul-09-24 | Initiated | Craig Hallum | Buy |
| May-23-24 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-12-24 | Initiated | Oppenheimer | Outperform |
View All
Skye Bioscience Inc Stock (SKYE) Latest News
Skye Bioscience stock target holds at $15 on obesity drug outlook - Investing.com
William Blair Forecasts Skye Bioscience Q2 Earnings - MarketBeat
(04/22/25) SKYE: A Speculative Play in the Weight Loss Drug Space - moneyshow.com
SKYE’s Market Ups and Downs: What’s Behind the 2023 Stock Performance? - investchronicle.com
Skye Bioscience, Inc. (NASDAQ:SKYE) Given Average Rating of “Buy” by Analysts - Defense World
William Blair Predicts Skye Bioscience Q1 Earnings - Defense World
Brokers Offer Predictions for Skye Bioscience Q1 Earnings - Defense World
Analysts Set Skye Bioscience, Inc. (NASDAQ:SKYE) PT at $16.60 - Defense World
Brokers Issue Forecasts for Skye Bioscience Q2 Earnings - Defense World
A Weight Loss Drug Candidate Essentially For Free As Skye Bioscience Is Trading At Cash Value - Seeking Alpha
Mural's Big Shake-Up, Skye's Weight Loss Win, And Janover's Crypto Bet - Finimize
Skye Bioscience reports promising obesity treatment study By Investing.com - Investing.com South Africa
Skye Bioscience's Obesity Candidate Shows 30% Weight Loss When Combined With Eli Lilly's Blockbuster Drug In Animal Models - Benzinga
Skye Bioscience (SKYE) Schedules Key Meetings at Biopharma Symposium - GuruFocus
Crude Oil Moves Lower; Citigroup Posts Upbeat Results - Benzinga
Skye Bioscience soars after experimental weight-loss drug shows promise in mice - TradingView
Nasdaq Surges 100 Points; Bank of America Earnings Top Views - Benzinga
Skye Bioscience Demonstrates Over 30% Weight Loss With Nimacimab And Tirzepatide Combination In Preclinical Model - marketscreener.com
Skye Bioscience's (SKYE) Nimacimab Shows Promising Weight Loss R - GuruFocus
Skye Bioscience Demonstrates Over 30% Weight Loss with Nimacimab - GuruFocus
Skye Bioscience Demonstrates Over 30% Weight Loss with Nimacimab and Tirzepatide Combination in Preclinical Model | SKYE Stock News - GuruFocus
Skye Bioscience reports promising obesity treatment study - Investing.com
Skye Bioscience Demonstrates Over 30% Weight Loss with - GlobeNewswire
Skye Bioscience (SKYE) Demonstrates Over 30% Weight Loss with Nimacimab and Tirzepatide Combination in Preclinical Model - StreetInsider
Revolutionary Obesity Drug Combo Shows 30% Weight Loss Success in Latest Trial Data - Stock Titan
Skye Bioscience to Conduct Meetings at Piper Sandler Conference - GuruFocus
Major Obesity Drug Developer Skye Bio Takes Center Stage at Prestigious Investor Conference - Stock Titan
Skye Bioscience (NASDAQ:SKYE) Shares Down 50.8% – Here’s Why - Defense World
Skye Bioscience (NASDAQ:SKYE) Trading Down 50.8% – What’s Next? - Defense World
Skye Bioscience, Inc. Investigated by Shareholder Rights AdvocatesInvestors Should Contact Levi & Korsinsky Regarding Potential Securities Law ViolationsSKYE - ACCESS Newswire
Charles Schwab Investment Management Inc. Has $176,000 Position in Skye Bioscience, Inc. (NASDAQ:SKYE) - Defense World
Charles Schwab Investment Management Inc. Grows Stock Position in Skye Bioscience, Inc. (NASDAQ:SKYE) - Defense World
10,142 Shares in Skye Bioscience, Inc. (NASDAQ:SKYE) Acquired by Virtu Financial LLC - Defense World
Virtu Financial LLC Invests $29,000 in Skye Bioscience, Inc. (NASDAQ:SKYE) - Defense World
Skye Bioscience, Inc. (NASDAQ:SKYE) Receives Consensus Rating of “Buy” from Analysts - Defense World
Skye Bioscience, Inc. (NASDAQ:SKYE) Receives $18.00 Average Price Target from Analysts - Defense World
Skye Bioscience, Inc. (NASDAQ:SKYE) Given Consensus Recommendation of "Buy" by Analysts - MarketBeat
Skye Bioscience, Inc. (PNK:SKYE) Q4 2024 Earnings Call Transcript - MSN
Skye Bioscience (NASDAQ:SKYE) Receives Outperform Rating from William Blair - MarketBeat
Skye Bioscience promotes Tu Diep to COO post - The Pharma Letter
Skye Bioscience (NASDAQ:SKYE) Price Target Cut to $14.00 by Analysts at Craig Hallum - MarketBeat
Skye Bioscience (NASDAQ:SKYE) Announces Quarterly Earnings Results - MarketBeat
Skye Bioscience’s SWOT analysis: novel obesity drug stock faces pivotal year - Investing.com Canada
Craig Hallum Cuts Skye Bioscience (NASDAQ:SKYE) Price Target to $14.00 - Defense World
Skye Bioscience’s (SKYE) “Outperform” Rating Reiterated at William Blair - Defense World
Craig Hallum Issues Pessimistic Forecast for Skye Bioscience (NASDAQ:SKYE) Stock Price - Defense World
Skye Bioscience Inc Stock (SKYE) Financials Data
Revenue
Net Income
Cash Flow
EPS
Skye Bioscience Inc Stock (SKYE) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Diep Tuan Tu | Chief Development Officer |
Nov 15 '24 |
Sale |
5.55 |
85 |
472 |
101,748 |
| ARSENAULT KAITLYN | Chief Financial Officer |
Nov 18 '24 |
Sale |
4.99 |
43,206 |
215,598 |
166,342 |
| ARSENAULT KAITLYN | Chief Financial Officer |
Nov 15 '24 |
Sale |
5.55 |
190 |
1,054 |
209,548 |
| DHILLON PUNIT | Chief Executive Officer |
Nov 18 '24 |
Sale |
4.99 |
82,546 |
411,905 |
329,823 |
| DHILLON PUNIT | Chief Executive Officer |
Nov 15 '24 |
Sale |
5.55 |
364 |
2,020 |
412,369 |
| Grayson Paul A. | Director |
Nov 18 '24 |
Sale |
4.99 |
86,244 |
430,358 |
259,701 |
| Grayson Paul A. | Director |
Nov 15 '24 |
Sale |
5.55 |
307 |
1,704 |
345,945 |
0.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):